<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890253</url>
  </required_header>
  <id_info>
    <org_study_id>CILT08</org_study_id>
    <nct_id>NCT00890253</nct_id>
  </id_info>
  <brief_title>Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation</brief_title>
  <acronym>CILT</acronym>
  <official_title>A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free De-novo Immunosuppression After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armin Goralczyk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, non-randomized two stage monocentric phase II clinical trial to evaluate a
      de-novo calcineurin-inhibitor (CNI)-free immunosuppressive regimen based on induction therapy
      with anti-CD25 monoclonal anti-body (basiliximab), mycophenolic acid (MPA), and mammalian
      target of rapamycin (mTOR) - inhibition with everolimus to determine its safety and to
      investigate the preliminary efficacy in patients with impaired renal function at the
      time-point of liver transplantation (OLT) with regards to the incidence of steroid resistant
      acute rejection within the first 30 days after liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steroid resistant rejection</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid resistant rejection</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated glomerular filtration rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on renal replacement therapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>CNI-free Immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab (Simulect)</intervention_name>
    <description>20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT</description>
    <arm_group_label>CNI-free Immunosuppression</arm_group_label>
    <other_name>Basiliximab: Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT</description>
    <arm_group_label>CNI-free Immunosuppression</arm_group_label>
    <other_name>Enteric-coated mycophenolate sodium: EC-MPS, Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>1 mg q12 everolimus (Certican) po starting on 10th post-operative day</description>
    <arm_group_label>CNI-free Immunosuppression</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg</description>
    <arm_group_label>CNI-free Immunosuppression</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing primary liver transplantation.

          2. Patients older than 18 years.

          3. Patients with a hepatorenal syndrome.

          4. Female patients of childbearing potential willing to perform a highly effective
             contraception during the study and 12 weeks after conclusion of study participation.

          5. eGFR &lt; 50 ml/min at the time point of transplantation.

          6. Serum creatinine levels &gt; 1.5 mg/dL at the time-point of transplantation.

        Exclusion Criteria:

          1. Patients with pre-transplant renal replacement therapy &gt; 14 days.

          2. Patients with a reason for renal impairment other than a hepatorenal syndrome.

          3. Patients with a known hypersensitivity to mTOR-inhibitors.

          4. Patients with a known hypersensitivity to mycophenolate acid.

          5. Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.

          6. Patients with platelets &lt; 50.000/nl prior to initiation of therapy with mTOR
             inhibition.

          7. Patients with triglycerides &gt; 350 mg/dl and cholesterol &gt; 300 mg/dl refractory to
             optimal medical treatment prior to initiation of therapy with mTOR inhibition.

          8. Severe systemic infections and wound-healing disturbances.

          9. Multiple organ graft recipients.

         10. Patients with signs of a hepatic artery stenosis directly prior to initiation of
             therapy with everolimus.

         11. Pregnant women will not be included in the study.

         12. Patients with a psychological, familial, sociologic or geographic condition
             potentially hampering compliance with the study protocol and follow-up schedule.

         13. Patients under guardianship (e.g., individuals who are not able to freely give their
             informed consent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiman Obed, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Goettingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armin D Goralczyk, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Goettingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aiman Obed, Prof. Dr.</last_name>
    <phone>+49 551 3912296</phone>
    <email>aobed@chirurgie-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armin D Goralczyk, MD</last_name>
    <phone>+49 551 3914638</phone>
    <email>agoralczyk@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin D Goralczyk, Dr.</last_name>
      <phone>+49 551 398490</phone>
      <email>agoralczyk@med.uni-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Aiman Obed, PD Dr.</last_name>
      <phone>+49 551 39 12296</phone>
      <email>aobed@chirurgie-goettingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Aiman Obed, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin D Goralczyk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>September 14, 2011</last_update_submitted>
  <last_update_submitted_qc>September 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Goettingen</investigator_affiliation>
    <investigator_full_name>Armin Goralczyk</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Renal impairment</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Chronic Renal Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

